Regeneron Pharmaceuticals' Research & Development rose 16.00% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 billion, marking a year-over-year increase of 15.09%. This contributed to the annual value of $5.1 billion for FY2024, which is 15.61% up from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Research & Development of $1.5 billion as of Q3 2025, which was up 3.75% from $1.4 billion recorded in Q2 2025.
Regeneron Pharmaceuticals' Research & Development's 5-year high stood at $1.5 billion during Q3 2025, with a 5-year trough of $665.4 million in Q3 2021.
Its 3-year average for Research & Development is $1.3 billion, with a median of $1.2 billion in 2024.
Per our database at Business Quant, Regeneron Pharmaceuticals' Research & Development declined by 2.80% in 2021 and then skyrocketed by 41.42% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Research & Development (Quarterly) stood at $737.6 million in 2021, then surged by 41.42% to $1.0 billion in 2022, then increased by 12.86% to $1.2 billion in 2023, then climbed by 19.95% to $1.4 billion in 2024, then rose by 16.00% to $1.5 billion in 2025.
Its Research & Development stands at $1.5 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.3 billion for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value